Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.46 |
| ▸ | CA1 | P00915 | 6/20 | 0.46 |
| ▸ | CA2 | P00918 | 6/20 | 0.46 |
| ▸ | CA9 | Q16790 | 6/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.44 |
| ▸ | APP | P05067 | 10/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2512607 | 0.95 | CA12 (0.47) | CA12CA1CA2CA9CA7 | |
| SCHEMBL1027525 | 0.89 | MMP2 (0.45) | CA12CA1CA2CA9CA7 | |
| SCHEMBL19874580 | 0.89 | CA12 (0.52) | CA12CA1CA2CA9CA7 | |
| SCHEMBL19874474 | 0.89 | CA12 (0.52) | CA12CA1CA2CA9CA7 | |
| SCHEMBL13600617 | 0.85 | CA12 (0.49) | CA12CA1CA2CA9CA7 | |
| SCHEMBL2513630 | 0.83 | CA12 (0.50) | CA12CA1CA2CA9CA7 | |
| SCHEMBL991363 | 0.82 | TSHR (0.64) | CA12CA1CA2CA9CA7 | |
| SCHEMBL232895 | 0.81 | TSHR (0.68) | CA12CA1CA2CA9CA7 | |
| SCHEMBL15866086 | 0.81 | ALDH1A1 (0.43) | CA12CA1CA2CA9CA7 | |
| SCHEMBL3369946 | 0.81 | TSHR (0.62) | CA12CA1CA2CA9CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034810-B2 | Matrix metalloproteinase inhibitors; antiinflammatory agengs; rheumatoid arthritis, osteoarthritis; antitumor, anticarcinogenic, and antimetastasis agents; respiratory system disorders, chronic obstructive pulmonary disease, deblocking, deprotecting | NOVARTIS AG (CH) | 2011-10-11 | — | — | US | disclosed |
| EP-1202961-B1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2010-01-20 | — | — | EP | disclosed |
| EP-2085379-A1 | Arylsulfonamido-substituted hydroxamic acid derivatives | Novartis AG (CH) | 2009-08-05 | — | — | EP | disclosed |
| US-20080275127-A1 | Arylsulfonamido-substituted hydroxamic acid derivatives | BREITENSTEIN WERNER | 2008-11-06 | — | — | US | disclosed |
| US-7138432-B1 | Arylsulfonamido-substituted hydroxamic acid derivatives | NOVARTIS AG (CH) | 2006-11-21 | — | — | US | disclosed |
| EP-1202961-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | Novartis AG (CH) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001010827-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275127-A1 | Arylsulfonamido-substituted hydroxamic acid derivatives | MMP13, MMP2, MMP1 | CA12 272/4885CA1 94/4885CA2 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.